Avadel Pharmaceuticals Gains FDA Approval for LUMRYZ

Avadel Pharmaceuticals ( (AVDL) ) has shared an update.

Avadel Pharmaceuticals has received FDA approval for LUMRYZ, a once-at-bedtime treatment for cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy. This marks a significant advancement for the narcolepsy community, allowing pediatric patients to benefit from a treatment that does not require waking up during the night. The FDA has also granted LUMRYZ Orphan Drug Exclusivity for pediatric use until 2031, underscoring its importance in improving patient care by avoiding the disruption of traditional twice-nightly dosing.

See more insights into AVDL stock on TipRanks’ Stock Analysis page.